Pharmacy

With their unique roles, pharmacists are moving away from being drug dispensers to becoming consultants in ACO models

Regulatory scrutiny will prevent drug plans managers from holding down costs for consumers

The new product was prompted by a recognition of the need for additional treatment options in the treatment of schizophrenia

Plans are offering input to manufacturers during drug development process.

Although generally satisfied with global cancer research progress, the public believes it takes too long for new cancer drugs to reach patients.

FDA approved 39 innovative drug therapies in 2012, the most new drug approvals in the U.S. since 1996.

An FDA advisory committee voted in favor of moving hydrocodone combination drugs into the restrictive “Schedule II” category of controlled substances.

ARBs and ACE inhibitors prolong life and help patients maintain daily living activities.

The government requires Part D plans to offer MTM services and report outcomes.

The specialty pharmacy market is currently fragmented with extreme variation in knowledge and education, patient care management, service, and outcomes.

Nine action points help payers handle site of administration for biologics.

Stem cells could successfully treat chronic conditions with significant cost savings.

New standards released by the USP seek to reduce medication compliance issues.

With half of prescriptions not being taken as prescribed, experts indicate that more attention needs to be given to medication adherence.

Drugs remain potent long after the expiration date

Plans can help reduce prescription drug abuse by advocating appropriate use.

Symptoms of insomnia can be treated with several different drugs, but be aware of side effects.

Despite front-end scrutiny, payers seek audit process to improve high-cost specialty pharmacies.

Part D program exceeds industry expectations

Asthma medications for children must match a child's ability to understand and control treatment of symptoms.

Oncology pathways can lead to quality programs and more cost-effective care for cancer patients.

Are drug-price guarantees here to stay?

The face of pharmacy benefit management continues to change in the wake of the $29.1 billion merger.

In spite of a drug pipeline that produced 34 new drugs moving to the market, U.S. spending on prescription drugs rose a negligible amount in 2011, according to a report from IMS Institute.

Prior authorization doesn't have to rely on paper forms and telephone requests.